Regeneron, Tessera to advance gene editing therapy for AATD: Deals Report

As seven-year-old Tessera nears the clinic with its first gene editing programs, the well-funded company has added $150 million to its till via a deal with Regeneron for its AAT deficiency treatment.

Tessera Therapeutics Inc. will work alongside Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on the program, with Tessera leading a first-in-human program and Regeneron shepherding later-stage development. The companies intend to split costs and profits 50-50 for the therapy, TSRA-196. Tessera expects to submit an IND for the program by year-end...